Dr. Grey AI

Ipamorelin

Peptide

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective growth hormone secretagogue. It stimulates growth hormone release from the pituitary gland by binding to the ghrelin/GHSR-1a receptor, with notable selectivity that does not significantly affect ACTH or cortisol levels, distinguishing it from other growth hormone releasing peptides.

Quick Answer

What it is

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective growth hormone secretagogue. It stimulates growth hormone release from the pituitary gland by binding to the ghrelin/GHSR-1a receptor, with notable selectivity that does not significantly affect ACTH or cortisol levels, distinguishing it from other growth hormone releasing peptides.

Key findings

  • Grade A: Growth Hormone Release (Metabolic Health)
  • Grade B: Longitudinal Bone Growth (Bone Health)
  • Grade B: Bone Mineral Content (Bone Health)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Ipamorelin

Quick Facts: Ipamorelin

  • Best Evidence:Grade A
  • Conditions Studied:4
  • Research Outcomes:9
  • Grade A Findings:1
  • Grade B Findings:6
  • Key Effect:Metabolic Health
A1
B6
C2
D0
4 conditions ¡ 9 outcomes

Detailed Outcomes

|
A
Growth Hormone Release
Ipamorelin potently stimulates growth hormone release in a dose-dependent manner, with effects comparable to GHRP-6 but without affecting cortisol or ACTH levels.
large↑Improves
B
Longitudinal Bone Growth
In animal studies, ipamorelin dose-dependently increased longitudinal bone growth rate from 42 Îźm/day to 52 Îźm/day, with pronounced effects on body weight gain.
moderate↑Improves
B
Bone Mineral Content
12-week treatment with ipamorelin increased total tibial and vertebral bone mineral content in adult rats, primarily through increased bone dimensions rather than volumetric density.
moderate↑Improves
B
Glucocorticoid-Induced Bone Loss
Ipamorelin counteracted glucocorticoid-induced decreases in bone formation, with periosteal bone formation rate increasing four-fold when combined with glucocorticoids.
moderate↓Improves
B
Muscle Strength
Maximum tetanic muscle tension was significantly increased in animals receiving ipamorelin combined with glucocorticoids, counteracting steroid-induced muscle weakness.
moderate↑Improves
B
Body Weight
Ipamorelin treatment showed dose-dependent effects on body weight gain in animal models, consistent with growth hormone-mediated anabolic effects.
small↑Worsens
C
Gastric Motility
Ipamorelin demonstrated dose-dependent improvement in gastric emptying in rodent models of postoperative ileus, though human clinical trials showed no significant difference versus placebo.
moderate↑Improves
C
Postoperative Recovery
In a randomized controlled trial of bowel resection patients, ipamorelin was well-tolerated but showed no significant differences versus placebo in time to first bowel movement or hospital discharge.
none

Research Citations (22)

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
(2020)
PMID: 32175416
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
(2014)
PMID: 25331030
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
(2012)
PMID: 27186127
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus
(2009)
PMID: 19289567
Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.
(2003)
PMID: 14630569
Effect of the growth hormone secretagogue, ipamorelin, on markers of bone turnover in female rats
(2002)
PMID: 12525634
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
(2002)
PMID: 12168778
The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.
(2002)
PMID: 12204475
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
(2001)
PMID: 11735244
Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.
(2001)
PMID: 11162489

Related Peptides

Sermorelin

Peptide

3 shared conditions ¡ 18 outcomes

Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency. Sermorelin stimulates natural GH release from the pituitary gland through the hypothalamic-pituitary axis, producing physiological GH patterns with built-in safety through somatostatin feedback regulation.